|
| Author | year | Number (T/C) | Gender (M/F) | Age (T/C) | Randomization | Intervention | Treatment duration (d) | Outcomes |
| T/C | CT in both group |
|
| Cheng | 2011 | 32/35 | 40/27 | 49.95 ± 14/46.24 ± 15.4 | RNT | O-XQLD (300 ml/d) + CT/CT | Budesonide powder (400∼800 μg/d) | 14 | CER; FEV1 |
|
| Cheng | 2011 | 24/24 | 23/25 | 54.3 ± 6.4/55.6 ± 5.7 | RNT | M-XQLD (1dose/d) + CT/CT | Budesonide aerosol (200–800 mg/d) | 14 | CER; FEV1; PEF |
|
| Fang | 2015 | 56/56 | 66/46 | 55.1 ± 10.4/54.8 ± 10.2 | RNT | M-XQLD (400 ml/d) + CT/CT | Budesonide aerosol (1600 μg/d) | 14 | CER, SS |
|
| Guo | 2017 | 50/50 | 46/54 | 41.61 ± 3.10/41.06 ± 3.09 | RNT | M-XQLD (2dose/d) + CT/CT | Budesonide formoterol powder (160 μg/d) | 14 | CER; FEV1; PEF |
|
| Guo | 2018 | 30/30 | Unclear | 18–65 | Unclear | M-XQLD(400 ml/d) + CT/CT | Budesonide formoterol powder (160 μg/4.5 μg) | 14 | FVC; PEF; Ig E |
|
| Huang | 2008 | 32/32 | 37/27 | 42.6 ± 6.13/44.32 ± 6.18 | Unclear | M-XQLD (400 ml/d) + CT/CT | Becotide aerosol (500 μg/d) | 10 | CER; FEV1; PEF; IgE; EOS |
|
| Huang | 2016 | 44/44 | 55/33 | 40.5 ± 10.2/39.8 ± 9.8 | Unclear | O-XQLD (1dose/d) + CT/CT | Bronchodilator agent + glucocorticoid | 14 | CER; EOS |
|
| Huang | 2017 | 22/22 | 31/13 | 41.24 ± 1.23/41.21 ± 1.26 | Unclear | XQLG (3 bags/d) + CT/CT | Salmeterol fluticasone powder (2 dose/d) | 7 | FEV1; PEF; FVC |
|
| Huang | 2012 | 39/39 | 33/45 | 39.8 ± 9.8/40.6 ± 10.3 | Unclear | O-XQLD (1dose/d) + CT/CT | Bronchodilator agent + glucocorticoid | 14 | CER; EOS |
|
| Jiang | 2016 | 26/26 | 29/23 | 18–65 | RNT | XQLG (3bags/d) + CT/CT | Salmeterol fluticasone inhalant (100-500 μg/d) | 7 | CER; FEV1; PEF; FVC |
|
| Jiang | 2015 | 40/40 | 22/58 | 42.34 ± 4.21/44.34 ± 4.68 | RNT | M-XQLD (100 ml/d) + CT/CT | 80 mg prednisone + 5 mg ventolin (2-3 dose/d) | 7 | CER; FEV1; EOS |
|
| Li | 2018 | 45/45 | 43/47 | 44.6 ± 8.7/43.6 ± 9.6 | Unclear | M-XQLD (2 dose/d) + CT/CT | Aminophylline + glucocorticoid + antibiotics | 14 | CER; IgE; EOS |
|
| Li | 2019 | 66/66 | 71/61 | 18–65 | RNT | XQLG (3 bags/d) + CT/CT | Budesonide aerosol (2-3 dose/d) | 7 | CER; FEV1; PEF; FVC; |
|
| Lin | 2018 | 40/40 | 43/37 | 40.58/40.49 | RNT | O-XQLD (1 dose/d) + CT/CT | Salmeterol fluticasone inhalant (100-500 μg/d) | 7 | CER; EOS |
|
| Lin | 2003 | 23/20 | 23/20 | 41/40 | RNT | M-XQLD (1 dose/d) + CT/CT | Receptor agonists, glucocorticoids, and antibiotics | 14 | CER; FEV1; FVC; Ig E |
|
| Liu | 2017 | 36/36 | 39/33 | 29.16 ± 4.21/29.06 ± 4.35 | RNT | M-XQLD (400 ml/d) + CT/CT | Bronchodilator agent + glucocorticoid | 14 | CER; EOS |
|
| Liu | 2016 | 100/100 | 136/54 | 26.2 ± 3.5/25.9 ± 4.5 | Unclear | O-XQLD (200 ml/d) + CT/CT | Bronchodilator agent + glucocorticoid | 7 | CER; FEV1; |
|
| Liu | 2018 | 30/30 | 31/29 | 50 ± 2.1/50 ± 2.5 | Unclear | M-XQLD (100 ml/d) + CT/CT | 10 mg montelukast + 80 μg budesonide aerosol (2 dose/d) | 14 | CER; AR |
|
| Liu | 2014 | 38/38 | 42/34 | 47.9 ± 4.9 | Unclear | XQLM (60 ml/d) + CT/CT | Salbutamol aerosol (0.4 mg/d) | 14 | CER; FEV1; FVC; |
|
| Lu | 2017 | 35/34 | 43/26 | 9.16 ± 2.85/9.47 ± 2.41 | RNT | XQLG (2 dose/d) + CT/CT | 100 μg fluticasone propionate + 50 μg salmeterol (1 dose/d) | 7 | CER; Ig E |
|
| Luo | 2011 | 30/30 | 27/33 | 40.1 ± 10.2/44.0 ± 10.2 | RNT | O-XQLD (1 dose/d) + CT/CT | Bronchodilator Agent + glucocorticoid | 10 | CER; EOS |
|
| Shi | 2009 | 40/40 | 46/34 | 45.3 ± 11.3/43.2 ± 11.6 | Admission time | M-XQLD (unclear) + CT/CT | Theophylline + long-acting beta agonists + glucocorticoids | 10 | CER; IgE; EOS |
|
| Sui | 2014 | 42/42 | 41/43 | 66.3 ± 10.46/66.26 ± 10.58 | RNT | M-XQLD (300 ml/d) + CT/CT | Salbutamol aerosol (0.4 mg/d) | 14 | CER; SS |
|
| Wan | 2014 | 22/22 | 21/23 | 67.62 ± 4.79/42.9 ± 9.73 | Unclear | M-XQLD (1 dose/d) + CT/CT | Bronchodilator agent + theophylline + glucocorticoid | 7 | CER; IgE; EOS |
|
| Wen | 2016 | 40/40 | 45/35 | 26.2 ± 3.5/25.9 ± 4.5 | Unclear | O-XQLD (100 ml/d) + CT/CT | Bronchodilator agent + glucocorticoid | 7 | CER; FEV1; |
|
| Wu | 2018 | 50/48 | 63/35 | 9.37 ± 1.25/8.95 ± 1.31 | Unclear | O-XQLD (1dose/d) + CT/CT | Budesonide aerosol (400 μg/d) | 14 | CER; SS |
|
| Xu | 2019 | 50/50 | 44/56 | 52.21 ± 2.11/52.26 ± 2.15 | Unclear | M-XQLD (1dose/d) + CT/CT | Salmeterol fluticasone inhalant (100–500 μg/d) | 7 | CER; EOS; PEF; FEV1 |
|
| Xu | 2011 | 41/37 | 55/23 | 42.13 ± 8.14/41.13 ± 7.32 | Unclear | O-XQLD (unclear) + CT/CT | Drugs of relieving cough and subsiding wheeze | 14 | CER; EOS; FEV1 |
|
| Zhang | 2005 | 33/30 | 37/26 | 3 months to 14 years old | Unclear | M-XQLD (1 dose/d) + CT/CT | Hydrocortisone succinate: 10 mg/(kg d) (3 doses/d) | 14 | CER; FEV1; PEF; EOS; IgE |
|
| Zhang | 2017 | 20/20 | 24/16 | 43.5 ± 9.7/44.6 ± 10.8 | Admission time | O-XQLD (300 ml/d) + CT/CT | Montelukas (10 mg/d) | 10 | CER; FEV1 |
|
| Zheng | 2012 | 32/32 | 29/35 | 45.3 ± 8.7/42.9 ± 9.1 | Admission time | O-XQLD (300 ml/d) + CT/CT | Salmeterol fluticasone inhalant + salbutamol | 7 | CER; FEV1; PEF; EOS |
|
| Zhou | 2013 | 52/53 | 39/66 | 41.95 ± 8.3/40.31 ± 6.9 | Unclear | M-XQLD9unclear) + CT/CT | Bronchodilator agent + glucocorticoid | 14 | CER; EOS |
|
| Zhou | 2018 | 50/50 | 53/47 | 41.7 ± 14.17/42.82 ± 13.58 | Odd even number | O-XQLD (1 dose/d) + CT/CT | Budesonide nasal spraying agent (200 μg/d) | 14 | CER; FEV1; PEF; IgE; EOS |
|
